QIBA CT Volumetry Biomarker Ctte (BC) Call
18 January 2016 at 11 AM CT
Draft Call Summary

In attendance:
Gregory Goldmacher, MD, PhD, MBA (Co-Chair)  Philip Judy, PhD  Kevin O’Donnell, MASc  Joe Koudelik
Jennifer Siegelman, MD, MPH (Co-Chair)  Bernd Kümmerlen, Dipl Phys  Marthony Robins, PhD  Julie Lisiecki
Hubert Beaumont, PhD  Roland Miezianko, PhD  Larry Schwartz, MD
Andrew Buckler, MS  James Mulshine, MD  Ying Tang, PhD
Matthew Fuld, PhD  Nancy Obuchowski, PhD  Pierre Tervé, MS
Ritu Gill, MD, MPH  Michael O’Connor, PhD

RSNA:

Planning for 2016 (Dr. Goldmacher)
- The group agreed on topics for upcoming WebEx calls through early April – in preparation for the QIBA Annual Meeting (Subsequent planning to follow in late spring.)
- Schedule to be distributed to the group.
- Suggested plan to invite stakeholders that are not regular call participants to achieve the following:
  - a better understanding of the goals of the Profile and the value of QIBA in serving the medical community
    - Need to clearly define the CT Vol BC mission
  - an opportunity for open feedback and dialogue
    {Co-chairs to provide any names / emails needed to RSNA staff for WebEx details.}

State of the CT Tumor Volume Change Profile (Mr. O’Donnell)
- A few open questions remain; Profile to be discussed with BC members on next call, 1/25 at 11 am CT
- Profile will then be sent to all CT Vol BC members for internal review prior to release for public comment
- The following remain under consideration:
  - Consideration to forgo the Field Test / Technically Confirmed phase (step 3) by
    - elevating the Profile Public Comment phase (step 2) status, and
    - releasing the Profile for public use at this new “publication” or public release phase
  - A “data registry” approach was another suggestion for moving the Profile forward
    - This may involve the use of consensus standards which are not quantitatively-supported, and would require revision to the claim language
    - Scans would be collected that are:
      a) acquired in a way that is Profile-compliant and
      b) helpful to QIBA in terms of evaluating whether Profile-compliant scans meet the claim
    - This approach would allow for QIBA statistical design and analysis related to the data collection effort
      - Substantial targeted marketing would be needed to drive data submission
      - Support of the Process Committee would be needed
  - These topics and others will be discussed beginning in mid-January prior to any official action

Action item: Mr. O’Donnell to continue updating the Profile for BC comment and review for the next call on January 25th

Next Call: Monday, Jan. 25th at 11 am CT | 2016 planning and review of the Profile and Next Steps